Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Anaplastic Thyroid Cancer: early-phase trial registry

1 of 6 indexed Anaplastic Thyroid Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Anaplastic Thyroid Cancer: 6 US clinical trials tracked, 1 recruiting.

Anaplastic Thyroid Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition anaplastic-thyroid-cancer

OPEN 1 | RECR 17% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Anaplastic Thyroid Cance (th…17%
Open-enrollment share among volume-matched conditions near Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anaplastic Thyroid Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anaplastic Thyroid Cancer is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Anaplastic Thyroid Cancer research.

    Memorial Sloan Kettering Cancer Center accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Anaplastic Thyroid Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 16 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Anaplastic Thyroid Cancer research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Named interventions

Most-linked intervention names on Anaplastic Thyroid Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Trametinib Drug
2 trials
Crolibulin Drug
1 trials
AIC100 CAR T Cells Biological
1 trials
Dabrafenib Drug
1 trials
XL092 Drug
1 trials
Cemiplimab Biological
1 trials
Paclitaxel Drug
1 trials
Cisplatin Drug
1 trials

US sites by state

Facility locations filed on Anaplastic Thyroid Cancer trials. A trial with sites in several states counts in each.

New York 3 trials
Texas 2 trials
New Jersey 2 trials
North Carolina 1 trials
Maryland 1 trials
Massachusetts 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anaplastic Thyroid Cancer page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Thyroid Cancer condition card totals 6 registered trials; most-linked intervention Trametinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.